## FORM 4

| UNITED STATES | SECURITIES AND    | EXCHANGE | COMMISSION |
|---------------|-------------------|----------|------------|
|               | Marchinetter D.O. | 00540    |            |

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

| 1. Name and Address of Reporting Pe<br>Henderson Ralph | erson*         | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>AMN HEALTHCARE SERVICES INC</u> [<br>AMN ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner<br>X Officer (give title Other (specify<br>below) below) |
|--|----------------|---|---|
| (Last) (First) (Middle)<br>12400 HIGH BLUFF DRIVE      |                | 3. Date of Earliest Transaction (Month/Day/Year)<br>01/03/2017                                      | Pres., Prof. Svc. & Staffing  |
| (Street)<br>SAN DIEGO CA<br>(City) (State)             | 92130<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |                  | ansaction Disposed Of (D) (Instr. 3, 4 and 5)<br>ode (Instr. |        | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership |            |  |
|---------------------------------|--|---|------------------|--|--------|---|---|---|------------|--|
|                                 |  |   | Code             | e V Amount (A) or Price                                      |        | Price   | Transaction(s)<br>(Instr. 3 and 4)                                |   | (Instr. 4) |  |
| Common Stock                    | 01/03/2017                                 |   | M <sup>(1)</sup> |  | 3,314  | A   | \$0.00  | 35,086  | D          |  |
| Common Stock                    | 01/03/2017                                 |   | F <sup>(2)</sup> |  | 1,414  | D   | \$38.5  | 33,672  | D          |  |
| Common Stock                    | 01/04/2017                                 |   | A <sup>(3)</sup> |  | 12,553 | A   | \$0.00  | 46,225  | D          |  |
| Common Stock                    | 01/04/2017                                 |   | F <sup>(2)</sup> |  | 4,704  | D   | \$38.925  | 41,521  | D          |  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|   | (0.9.) parts, character, cpriority control and coominities            |  |   |                              |   |            |       |  |                    |  |  |   |                              |  |  |
|---|---|--|---|------------------------------|---|------------|-------|--|--------------------|--|--|---|------------------------------|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | Derivative |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | Reported                     | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   | Code                         | v | (A)        | (D)   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   | Transaction(s)<br>(Instr. 4) |  |  |
| Restricted<br>Stock<br>Units                        | (4)   | 01/03/2017                                 |   | М                            |   |            | 3,314 | (5)  | (6)                | Common<br>Stock  | 3,314                                  | \$0.00  | 0                            | D  |  |
| Restricted<br>Stock<br>Units                        | (4)   | 01/04/2017                                 |   | A                            |   | 6,294      |       | (7)  | (6)                | Common<br>Stock  | 6,294                                  | \$0.00  | 6,294                        | D  |  |

#### Explanation of Responses:

1. Common Stock acquired on the vesting of Restricted Stock Units.

2. Number of shares withheld for tax purposes.

3. The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 3, 2014. The ultimate number of PRSUs that could have been earned and vested under this award depended on (1) the total shareholder return for the Company relative to the companies in the Russell 2000 Index as of December 31, 2013 for the 3-year period beginning on January 1, 2014 and ended December 31, 2016 ("Relative TSR") and (2) whether the Company's absolute total shareholder return for the same period was positive or negative (collectively, the "TSR Measurement"). The Compensation Committee performed the TSR Measurement for this award on January 4, 2017. The Company's Relative TSR measured in the 97th percentile and its absolute total shareholder return for the period was positive. Based on these results, the maximum amount of PRSUs for this award were deemed and vested.


4. The Restricted Stock Units were granted pursuant to the AMN Healthcare Equity Plan. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock.

5. The Restricted Stock Units were granted on January 3, 2014 and vest on the third anniversary of the grant date. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock.

6. Restricted Stock Units do not have an expiration date.

7. The Restricted Stock Units identified in this row were granted on January 4, 2017 and vest on the third anniversary of the grant date, provided, however, the Restricted Stock Units shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2017 fiscal year and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2018 fiscal year.

Remarks:



<u>01/05/2017</u> Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.